Our study found that PKM2 loss at the time of tumor initiation in a mouse model of STS driven by activation of oncogenic Kras and loss of p53 leads to delayed tumor onset and decreased tumor penetrance. The gene discussed is KRAS; the disease is telomere syndrome.